Limits...
A three species model to simulate application of Hyperbaric Oxygen Therapy to chronic wounds.

Flegg JA, McElwain DL, Byrne HM, Turner IW - PLoS Comput. Biol. (2009)

Bottom Line: Based on our modelling, we predict that intermittent HBOT will assist chronic wound healing while normobaric oxygen is ineffective in treating such wounds.Furthermore, treatment should continue until healing is complete, and HBOT will not stimulate healing under all circumstances, leading us to conclude that finding the right protocol for an individual patient is crucial if HBOT is to be effective.The work of this paper can, in some way, highlight which patients are most likely to respond well to HBOT (for example, those with a good arterial supply), and thus has the potential to assist in improving both the success rate and hence the cost-effectiveness of this therapy.

View Article: PubMed Central - PubMed

Affiliation: School of Mathematical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.

ABSTRACT
Chronic wounds are a significant socioeconomic problem for governments worldwide. Approximately 15% of people who suffer from diabetes will experience a lower-limb ulcer at some stage of their lives, and 24% of these wounds will ultimately result in amputation of the lower limb. Hyperbaric Oxygen Therapy (HBOT) has been shown to aid the healing of chronic wounds; however, the causal reasons for the improved healing remain unclear and hence current HBOT protocols remain empirical. Here we develop a three-species mathematical model of wound healing that is used to simulate the application of hyperbaric oxygen therapy in the treatment of wounds. Based on our modelling, we predict that intermittent HBOT will assist chronic wound healing while normobaric oxygen is ineffective in treating such wounds. Furthermore, treatment should continue until healing is complete, and HBOT will not stimulate healing under all circumstances, leading us to conclude that finding the right protocol for an individual patient is crucial if HBOT is to be effective. We provide constraints that depend on the model parameters for the range of HBOT protocols that will stimulate healing. More specifically, we predict that patients with a poor arterial supply of oxygen, high consumption of oxygen by the wound tissue, chronically hypoxic wounds, and/or a dysfunctional endothelial cell response to oxygen are at risk of nonresponsiveness to HBOT. The work of this paper can, in some way, highlight which patients are most likely to respond well to HBOT (for example, those with a good arterial supply), and thus has the potential to assist in improving both the success rate and hence the cost-effectiveness of this therapy.

Show MeSH

Related in: MedlinePlus

Simulation of the treatment of a chronic wound with HBOT for 1.5 hours per day.Multiple day intervals are shown (dark blue = 2, red = 4, green = 6, black = 8, yellow = 10, light blue = 12, pink = 14). Parameter values: as per Fig 2, except .
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2710516&req=5

pcbi-1000451-g003: Simulation of the treatment of a chronic wound with HBOT for 1.5 hours per day.Multiple day intervals are shown (dark blue = 2, red = 4, green = 6, black = 8, yellow = 10, light blue = 12, pink = 14). Parameter values: as per Fig 2, except .

Mentions: We now investigate the impact of HBOT on the healing of a chronic wound. The strength and duration of HBOT are given by the parameters and in the model, respectively. The parameter is a measure of the relative increase in supply of oxygen during HBOT compared to times of no treatment. Fig 3 shows such a chronic wound situation under HBOT with for hours per day (that is, of a day). A value of is associated with 100% oxygen at a pressure of just under 3atm (see Materials and Methods Section), which is a reasonable treatment protocol. We note from the simulation that the capillary tip density in the chronic wound reaches highly elevated levels under treament and that healing is quickly initiated in the chronic wound.


A three species model to simulate application of Hyperbaric Oxygen Therapy to chronic wounds.

Flegg JA, McElwain DL, Byrne HM, Turner IW - PLoS Comput. Biol. (2009)

Simulation of the treatment of a chronic wound with HBOT for 1.5 hours per day.Multiple day intervals are shown (dark blue = 2, red = 4, green = 6, black = 8, yellow = 10, light blue = 12, pink = 14). Parameter values: as per Fig 2, except .
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2710516&req=5

pcbi-1000451-g003: Simulation of the treatment of a chronic wound with HBOT for 1.5 hours per day.Multiple day intervals are shown (dark blue = 2, red = 4, green = 6, black = 8, yellow = 10, light blue = 12, pink = 14). Parameter values: as per Fig 2, except .
Mentions: We now investigate the impact of HBOT on the healing of a chronic wound. The strength and duration of HBOT are given by the parameters and in the model, respectively. The parameter is a measure of the relative increase in supply of oxygen during HBOT compared to times of no treatment. Fig 3 shows such a chronic wound situation under HBOT with for hours per day (that is, of a day). A value of is associated with 100% oxygen at a pressure of just under 3atm (see Materials and Methods Section), which is a reasonable treatment protocol. We note from the simulation that the capillary tip density in the chronic wound reaches highly elevated levels under treament and that healing is quickly initiated in the chronic wound.

Bottom Line: Based on our modelling, we predict that intermittent HBOT will assist chronic wound healing while normobaric oxygen is ineffective in treating such wounds.Furthermore, treatment should continue until healing is complete, and HBOT will not stimulate healing under all circumstances, leading us to conclude that finding the right protocol for an individual patient is crucial if HBOT is to be effective.The work of this paper can, in some way, highlight which patients are most likely to respond well to HBOT (for example, those with a good arterial supply), and thus has the potential to assist in improving both the success rate and hence the cost-effectiveness of this therapy.

View Article: PubMed Central - PubMed

Affiliation: School of Mathematical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.

ABSTRACT
Chronic wounds are a significant socioeconomic problem for governments worldwide. Approximately 15% of people who suffer from diabetes will experience a lower-limb ulcer at some stage of their lives, and 24% of these wounds will ultimately result in amputation of the lower limb. Hyperbaric Oxygen Therapy (HBOT) has been shown to aid the healing of chronic wounds; however, the causal reasons for the improved healing remain unclear and hence current HBOT protocols remain empirical. Here we develop a three-species mathematical model of wound healing that is used to simulate the application of hyperbaric oxygen therapy in the treatment of wounds. Based on our modelling, we predict that intermittent HBOT will assist chronic wound healing while normobaric oxygen is ineffective in treating such wounds. Furthermore, treatment should continue until healing is complete, and HBOT will not stimulate healing under all circumstances, leading us to conclude that finding the right protocol for an individual patient is crucial if HBOT is to be effective. We provide constraints that depend on the model parameters for the range of HBOT protocols that will stimulate healing. More specifically, we predict that patients with a poor arterial supply of oxygen, high consumption of oxygen by the wound tissue, chronically hypoxic wounds, and/or a dysfunctional endothelial cell response to oxygen are at risk of nonresponsiveness to HBOT. The work of this paper can, in some way, highlight which patients are most likely to respond well to HBOT (for example, those with a good arterial supply), and thus has the potential to assist in improving both the success rate and hence the cost-effectiveness of this therapy.

Show MeSH
Related in: MedlinePlus